ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Primary pulmonary hypertension 1
Gene/Gene Panel: BMPR2
Context: Adult
Date
Status
Outcomes-Interventions
Notes
2023/05/03
Released (Under revision)
1.2.4
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/03/14
Released
1.2.4
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/03/14
Released (Under revision)
1.2.3
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/02/21
Released
1.2.3
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2021/12/07
Released (Under revision)
1.2.2
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
2020/04/27
Released
1.2.2
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
2020/04/27
Released (Under revision)
1.2.1
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
2020/04/27
Released
1.2.1
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
2020/04/27
Released (Under revision)
1.2.0
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.2.0
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Annual echocardiogram (GroupA) 8CB
Avoidance of exacerbating exposures (GroupA) 7CC
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.1.0
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.1
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
Internal system migration related to score text replacement from E to N
2018/01/29
Released
1.0.0
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
¤ Powered by BCM's Genboree.